Saniona completes SAN2465 tox, CMC studies, targets IND filing by end-October 2026

Bitget2026/09/24 06:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Saniona completed toxicology and CMC work for SAN2465, clearing the package needed to support an IND filing.
IND submission to the FDA is targeted by end-October 2026, setting up first-in-human dosing plans.
Planned Phase 1 trial targets safety, tolerability, pharmacokinetics in healthy volunteers, with biomarker readouts to inform dose selection.
SAN2465 targets GABA-A α5 receptors for major depressive disorder, aiming for ketamine-like rapid onset with an oral profile.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Saniona completes SAN2465 tox, CMC studies, targets IND filing by end-October 2026

You may also like

Crypto prices